Logo image of XOMA

XOMA ROYALTY CORPORATION (XOMA) Stock Fundamental Analysis

NASDAQ:XOMA - Nasdaq - US98419J2069 - Common Stock - Currency: USD

25.67  -0.63 (-2.4%)

After market: 25.67 0 (0%)

Fundamental Rating

4

XOMA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. XOMA has a medium profitability rating, but doesn't score so well on its financial health evaluation. XOMA is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

XOMA had negative earnings in the past year.
XOMA had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: XOMA reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: XOMA reported negative operating cash flow in multiple years.
XOMA Yearly Net Income VS EBIT VS OCF VS FCFXOMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

XOMA has a Return On Assets of -8.74%. This is amongst the best in the industry. XOMA outperforms 84.95% of its industry peers.
With an excellent Return On Equity value of -21.96%, XOMA belongs to the best of the industry, outperforming 83.69% of the companies in the same industry.
With an excellent Return On Invested Capital value of 0.19%, XOMA belongs to the best of the industry, outperforming 91.22% of the companies in the same industry.
Industry RankSector Rank
ROA -8.74%
ROE -21.96%
ROIC 0.19%
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
XOMA Yearly ROA, ROE, ROICXOMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

The Operating Margin of XOMA (1.03%) is better than 91.58% of its industry peers.
The Profit Margin and Gross Margin are not available for XOMA so they could not be analyzed.
Industry RankSector Rank
OM 1.03%
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XOMA Yearly Profit, Operating, Gross MarginsXOMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so XOMA is destroying value.
XOMA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for XOMA has been increased compared to 5 years ago.
Compared to 1 year ago, XOMA has a worse debt to assets ratio.
XOMA Yearly Shares OutstandingXOMA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
XOMA Yearly Total Debt VS Total AssetsXOMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

XOMA has an Altman-Z score of -5.92. This is a bad value and indicates that XOMA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -5.92, XOMA is not doing good in the industry: 62.54% of the companies in the same industry are doing better.
XOMA has a Debt/Equity ratio of 1.18. This is a high value indicating a heavy dependency on external financing.
XOMA has a Debt to Equity ratio of 1.18. This is in the lower half of the industry: XOMA underperforms 78.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.18
Debt/FCF N/A
Altman-Z -5.92
ROIC/WACC0.02
WACC9.98%
XOMA Yearly LT Debt VS Equity VS FCFXOMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

XOMA has a Current Ratio of 5.54. This indicates that XOMA is financially healthy and has no problem in meeting its short term obligations.
XOMA has a Current ratio (5.54) which is in line with its industry peers.
A Quick Ratio of 5.54 indicates that XOMA has no problem at all paying its short term obligations.
XOMA's Quick ratio of 5.54 is in line compared to the rest of the industry. XOMA outperforms 58.60% of its industry peers.
Industry RankSector Rank
Current Ratio 5.54
Quick Ratio 5.54
XOMA Yearly Current Assets VS Current LiabilitesXOMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

XOMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.50%, which is quite impressive.
Looking at the last year, XOMA shows a very strong growth in Revenue. The Revenue has grown by 663.79%.
XOMA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.17% yearly.
EPS 1Y (TTM)52.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.98%
Revenue 1Y (TTM)663.79%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%967.92%

3.2 Future

The Earnings Per Share is expected to grow by 35.64% on average over the next years. This is a very strong growth
Based on estimates for the next years, XOMA will show a very strong growth in Revenue. The Revenue will grow by 33.09% on average per year.
EPS Next Y90.1%
EPS Next 2Y42.17%
EPS Next 3Y35.64%
EPS Next 5YN/A
Revenue Next Year67.38%
Revenue Next 2Y38.13%
Revenue Next 3Y33.09%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
XOMA Yearly Revenue VS EstimatesXOMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M
XOMA Yearly EPS VS EstimatesXOMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6 -8 -10

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XOMA. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 589.80, the valuation of XOMA can be described as expensive.
86.56% of the companies in the same industry are more expensive than XOMA, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.44, XOMA is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 589.8
XOMA Price Earnings VS Forward Price EarningsXOMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 200 400

4.2 Price Multiples

XOMA's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. XOMA is cheaper than 90.50% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 273.74
XOMA Per share dataXOMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as XOMA's earnings are expected to grow with 35.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.17%
EPS Next 3Y35.64%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XOMA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XOMA ROYALTY CORPORATION

NASDAQ:XOMA (7/18/2025, 8:21:20 PM)

After market: 25.67 0 (0%)

25.67

-0.63 (-2.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners62.7%
Inst Owner Change0%
Ins Owners1.39%
Ins Owner Change-34.6%
Market Cap307.27M
Analysts82
Price Target65.96 (156.95%)
Short Float %2.82%
Short Ratio5.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.47
Dividend Growth(5Y)N/A
DP-29.44%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)37.13%
Min EPS beat(2)-45.44%
Max EPS beat(2)119.7%
EPS beat(4)2
Avg EPS beat(4)56.23%
Min EPS beat(4)-256.98%
Max EPS beat(4)407.67%
EPS beat(8)3
Avg EPS beat(8)22.51%
EPS beat(12)3
Avg EPS beat(12)-16.39%
EPS beat(16)5
Avg EPS beat(16)-21.54%
Revenue beat(2)1
Avg Revenue beat(2)59.22%
Min Revenue beat(2)-2.38%
Max Revenue beat(2)120.82%
Revenue beat(4)3
Avg Revenue beat(4)39.22%
Min Revenue beat(4)-2.38%
Max Revenue beat(4)120.82%
Revenue beat(8)5
Avg Revenue beat(8)22.27%
Revenue beat(12)6
Avg Revenue beat(12)0.36%
Revenue beat(16)7
Avg Revenue beat(16)-7.52%
PT rev (1m)0%
PT rev (3m)-18.66%
EPS NQ rev (1m)18.47%
EPS NQ rev (3m)-7.64%
EPS NY rev (1m)63.18%
EPS NY rev (3m)64.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)25.65%
Revenue NY rev (1m)0%
Revenue NY rev (3m)49.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 589.8
P/S 6.92
P/FCF N/A
P/OCF N/A
P/B 3.63
P/tB 5.18
EV/EBITDA 273.74
EPS(TTM)-1.14
EYN/A
EPS(NY)0.04
Fwd EY0.17%
FCF(TTM)-2.24
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS3.71
BVpS7.07
TBVpS4.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.74%
ROE -21.96%
ROCE 0.24%
ROIC 0.19%
ROICexc 0.36%
ROICexgc 0.49%
OM 1.03%
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 1.18
Debt/FCF N/A
Debt/EBITDA 82.05
Cap/Depr 2651.64%
Cap/Sales 45.45%
Interest Coverage 0.04
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.54
Quick Ratio 5.54
Altman-Z -5.92
F-Score5
WACC9.98%
ROIC/WACC0.02
Cap/Depr(3y)7738.51%
Cap/Depr(5y)4653.1%
Cap/Sales(3y)108.05%
Cap/Sales(5y)64.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.98%
EPS Next Y90.1%
EPS Next 2Y42.17%
EPS Next 3Y35.64%
EPS Next 5YN/A
Revenue 1Y (TTM)663.79%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%967.92%
Revenue Next Year67.38%
Revenue Next 2Y38.13%
Revenue Next 3Y33.09%
Revenue Next 5YN/A
EBIT growth 1Y102%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year179.83%
EBIT Next 3Y51.02%
EBIT Next 5YN/A
FCF growth 1Y16.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.67%
OCF growth 3YN/A
OCF growth 5YN/A